Multi-cancer early detection (MCED) tests represent a breakthrough in medical science for their ability to identify multiple cancers with a single blood draw, thus improving mortality and morbidity outcomes.

In this article, RGA’s team of experts- Andrew Gaskell, Dr. Heather Lund, Raman Lalia- explore what this could mean for insurers and the challenges of modeling and quantifying MCED tests’ potential impact. Read more